Inflammation and Angiogenesis in Fibrotic Lung Disease

Michael P. Keane; Robert M. Strieter; Joseph P. Lynch; John A. Belperio

doi:10.1055/s-2006-957331

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2006; 27(6): 589-599
DOI: 10.1055/s-2006-957331

Inflammation and Angiogenesis in Fibrotic Lung Disease

Michael P. Keane¹ , Robert M. Strieter² , Joseph P. Lynch¹ III , John A. Belperio¹

¹Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine at UCLA, Los Angeles, California
²Department of Medicine, University of Virginia, Charlottesville, Virginia

Abstract

ABSTRACT

The pathogenesis of pulmonary fibrosis is poorly understood. Although inflammation has been presumed to have an important role in the development of fibrosis this has been questioned recently, particularly with regard to idiopathic pulmonary fibrosis (IPF). It is, however, increasingly recognized that the polarization of the inflammatory response toward a type 2 phenotype supports fibroproliferation. Increased attention has been on the role of noninflammatory structural cells such as the fibroblast, myofibroblast, epithelial cell, and endothelial cells. Furthermore, the origin of these cells appears to be multifactorial and includes resident cells, bone marrow-derived cells, and epithelial to mesenchymal transition. Increasing evidence supports the presence of vascular remodeling in fibrotic lung disease, although the precise role in the pathogenesis of fibrosis remains to be determined. Therefore, the pathogenesis of pulmonary fibrosis is complex and involves the interaction of multiple cell types and compartments within the lung.

KEYWORDS

Idiopathic pulmonary fibrosis - angiogenesis - fibrosis - fibroblasts - chemokines

Full Text

References

REFERENCES

1 Davidson J M. Wound repair. In: Gallin JI, Goldstein IM, Snyderman R Inflammation: Basic Principles and Clinical Correlates. New York; Raven 1992
2 Vaillant P, Menard O, Vignaud J-M, Martinet N, Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis. 1996; 51 145-152
3 Phan S H. New strategies for treatment of pulmonary fibrosis. Thorax. 1995; 50 415-421
4 Phan S H, Kunkel S L. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992; 18 29-43
5 Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax. 1993; 48 931-935
6 Kelly B G, Lok S S, Hasleton P S, Egan J J, Stewart J P. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002; 166 510-513
7 Mora A L, Torres-Gonzalez E, Rojas M et al.. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol 2006; 35 466-473
8 Zamo A, Poletti V, Reghellin D et al.. HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22 123-128
9 Tang Y W, Johnson J E, Browning P J et al.. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003; 41 2633-2640
10 Lok S S, Haider Y, Howell D, Stewart J P, Hasleton P S, Egan J J. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J. 2002; 20 1228-1232
11 Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol. 2001; 107 1001-1008
12 Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 1999; 250 273-283
13 Phan S H. Fibroblast phenotypes in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003; 29(Suppl 3) S87-S92
14 Bucala R, Spiegel L A, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994; 1 71-81
15 Moore B B, Kolodsick J E, Thannickal V J et al.. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol. 2005; 166 675-684
16 Abe R, Donnelly S C, Peng T, Bucala R, Metz C N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001; 166 7556-7562
17 Chesney J, Metz C, Stavitsky A B, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998; 160 419-425
18 Phillips R J, Burdick M D, Hong K et al.. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004; 114 438-446
19 Kalluri R, Neilson E G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003; 112 1776-1784
20 Iwano M, Plieth D, Danoff T M, Xue C, Okada H, Neilson E G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002; 110 341-350
21 Willis B C, Liebler J M, Luby-Phelps K et al.. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-{beta}1: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005; 166 1321-1332
22 Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication?. J Clin Invest. 2001; 107 1501-1502
23 Kolb M, Margetts P J, Anthony D C, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001; 107 1529-1536
24 King Jr T E, Schwarz M I, Brown K et al.. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001; 164 1025-1032
25 Collard H R, King Jr T E. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med. 2001; 110 326-328
26 Selman M, King T E, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134 136-151
27 Chandler D B. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med. 1990; 11 21-30
28 Christensen P J, Goodman R E, Pastoriza L, Moore B, Toews G B. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol. 1999; 155 1773-1779
29 Sime P J, Xing Z, Graham F L, Csaky K G, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor- beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997; 100 768-776
30 Sime P J, Marr R A, Gauldie D et al.. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol. 1998; 153 825-832
31 Miyazaki Y, Araki K, Vesin C et al.. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995; 96 250-259
32 Leung D Y, de Castro M, Szefler S J, Chrousos G P. Mechanisms of glucocorticoid-resistant asthma. Ann N Y Acad Sci. 1998; 840 735-746
33 Belperio J A, Keane M P, Burdick M D et al.. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001; 108 547-556
34 Trulock E P. Lung transplantation. Am J Respir Crit Care Med. 1997; 155 789-818
35 Flaherty K R, Travis W D, Colby T V et al.. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001; 164 1722-1727
36 Belperio J A, Dy M, Murray L et al.. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004; 173 4692-4698
37 Zhang Y, McCormick L L, Desai S R, Wu C, Gilliam A C. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002; 168 3088-3098
38 Luzina I G, Atamas S P, Wise R, Wigley F M, Xiao H Q, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol. 2002; 26 549-557
39 Antoniades H N, Neville-Golden J, Galanopoulos T, Kradin R L, Valente A J, Graves D T. Expression of monocyte chemoattractant protein-1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 1992; 89 5371-5375
40 Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005; 52 2889-2896
41 Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000; 12 59-63
42 Belperio J A, Keane M P, Arenberg D A et al.. CXC chemokines in angiogenesis. J Leukoc Biol. 2000; 68 1-8
43 Giri S N, Hyde D M, Marafino B J. Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem Med Metab Biol. 1986; 36 194-197
44 Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim F A, Dayer J M. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum. 1998; 41 2039-2047
45 Cornelissen A M, Von den Hoff J W, Maltha J C, Kuijpers-Jagtman A M. Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts. Arch Oral Biol. 1999; 44 541-547
46 Jaffe H A, Gao Z, Mori Y, Li L, Varga J. Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene. Exp Lung Res. 1999; 25 199-215
47 Brody A R, Bonner J C, Badgett A. Recombinant interferon-gamma reduces PDGF-induced lung fibroblast growth but stimulates PDGF production by alveolar macrophages in vitro. Chest. 1993; 103(Suppl 2) 121S-122S
48 Dimitroff C J, Pera P, Dall'Olio F et al.. Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells. Biochem Biophys Res Commun. 1999; 256 631-636
49 Keane M P, Belperio J A, Burdick M D, Strieter R M. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2001; 281 L92-L97
50 Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N. Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol. 2001; 280 L1128-L1137
51 Huaux F, Arras M, Tomasi D et al.. A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J Immunol. 2002; 169 2653-2661
52 Sakamoto H, Zhao L H, Jain F, Kradin R. IL-12p40( - / - ) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis. Exp Mol Pathol. 2002; 72 1-9
53 Segel M J, Cohen P Y, Izbicki G et al.. The role of interferon-{gamma} in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2003; 285 L1255-L1262
54 Chen E S, Greenlee B M, Wills-Karp M, Moller D R. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol. 2001; 24 545-555
55 Stout A J, Gresser I, Thompson D. Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol. 1993; 74 79-85
56 Hyde D M, Henderson T S, Giri S N, Tyler N K, Stovall M Y. Effect of murine gamma interferon on the cellular responses to bleomycin in mice. Exp Lung Res. 1988; 14 687-704
57 Gurujeyalakshmi G, Giri S N. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res. 1995; 21 791-808
58 Postlethwaite A E, Holness M A, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest. 1992; 90 1479-1485
59 Postlethwaite A E, Seyer J M. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest. 1991; 87 2147-2152
60 Rankin J A, Picarella D E, Geba G P et al.. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA. 1996; 93 7821-7825
61 Chensue S W, Warmington K, Ruth J H, Lukacs N, Kunkel S L. Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. [published erratum appears in J Immunol 1999 Mar 1;162(5):3106]. J Immunol. 1997; 159 3565-3573
62 Wills-Karp M, Luyimbazi J, Xu X et al.. Interleukin-13: central mediator of allergic asthma. [see comments]. Science. 1998; 282 2258-2261
63 Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998; 18 60-65
64 Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997; 24 328-332
65 Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001; 38 368-375
66 Oriente A, Fedarko N S, Pacocha S E, Huang S K, Lichtenstein L M, Essayan D M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther. 2000; 292 988-994
67 Zhu Z, Homer R J, Wang Z et al.. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999; 103 779-788
68 Lee C G, Homer R J, Zhu Z et al.. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001; 194 809-821
69 Lanone S, Zheng T, Zhu Z et al.. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest. 2002; 110 463-474
70 Kaviratne M, Hesse M, Leusink M et al.. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004; 173 4020-4029
71 Zhu Z, Ma B, Zheng T et al.. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2002; 168 2953-2962
72 Ma B, Zhu Z, Homer R J, Gerard C, Strieter R, Elias J A. The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2004; 172 1872-1881
73 Lee P J, Zhang X, Shan P et al.. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J Clin Invest. 2006; 116 163-173
74 Gharaee-Kermani M, Denholm E M, Phan S H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996; 271 17779-17784
75 Smith R E, Strieter R M, Phan S H et al.. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol. 1994; 153 4704-4712
76 Smith R E, Strieter R M, Phan S H, Kunkel S L. CC chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol. 1996; 15 693-702
77 Gu L, Tseng S, Horner R M, Tam C, Loda M, Rollins B J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000; 404 407-411
78 Hogaboam C M, Lukacs N W, Chensue S W, Strieter R M, Kunkel S L. Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4 + T cell activation. J Immunol. 1998; 160 4606-4614
79 Belperio J A, Dy M, Burdick M D et al.. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002; 27 419-427
80 Jakubzick C, Choi E S, Joshi B H et al.. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003; 171 2684-2693
81 Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol. 2000; 164 2745-2751
82 Moore B B, Paine III R, Christensen P J et al.. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol. 2001; 167 4368-4377
83 Moore B B, Peters-Golden M, Christensen P J et al.. Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol. 2003; 284 L342-L349
84 Wallace W AH, Ramage E A, Lamb D, Howie E M. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with crytogenic fibrosingalveolitis (CFA). Clin Exp Immunol. 1995; 101 436-441
85 Jakubzick C, Choi E S, Kunkel S L et al.. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol. 2004; 57 477-486
86 Jakubzick C, Choi E S, Carpenter K J et al.. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol. 2004; 164 1989-2001
87 Kuroki S, Ohta A, Sueoka N, Katoh O, Yamada H, Yamaguchi M. Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopeptide and interferon-γ in progressive fibrosis. Br J Rheumatol. 1995; 34 31-36
88 Raghu G, Brown K K, Bradford W Z et al.. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350 125-133
89 Mulligan M S, Jones M L, Vaporciyan A A, Howard M C, Ward P A. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol. 1993; 151 5666-5674
90 Standiford T J, Strieter R M, Lukacs N W, Kunkel S L. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol. 1995; 155 2222-2229
91 Greenberger M J, Strieter R M, Kunkel S L, Danforth J M, Goodman R E, Standiford T J. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol. 1995; 155 722-729
92 Lee C G, Homer R J, Cohn L et al.. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem. 2002; 277 35466-35474
93 Arai T, Abe K, Matsuoka H et al.. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol. 2000; 278 L914-L922
94 Driscoll K E, Carter J M, Howard B W et al.. Interleukin-10 regulates quartz-induced pulmonary inflammation in rats. Am J Physiol. 1998; 275(5 Pt 1) L887-L894
95 Huaux F, Louahed J, Hudspith B et al.. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol. 1998; 18 51-59
96 Arras M, Huaux F, Vink A et al.. Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. Am J Respir Cell Mol Biol. 2001; 24 368-375
97 Hoyle G W, Brody A R. IL-9 and lung fibrosis: a Th2 good guy?. Am J Respir Cell Mol Biol. 2001; 24 365-367
98 Rojas M, Xu J, Woods C R et al.. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005; 33 145-152
99 Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax. 1963; 18 225-237
100 Peao M ND, Aguas A P, DeSa C M, Grande N R. Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec. 1994; 238 57-67
101 Mitzner W, Lee W, Georgakopoulos D, Wagner E. Angiogenesis in the mouse lung. Am J Pathol. 2000; 157 93-101
102 Srisuma S, Biswal S S, Mitzner W A, Gallagher S J, Mai K H, Wagner E M. Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. Am J Respir Cell Mol Biol. 2003; 29 172-179
103 Keane M P, Arenberg D A, Lynch III J P et al.. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997; 159 1437-1443
104 Keane M P, Belperio J A, Arenberg D A et al.. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol. 1999; 163 5686-5692
105 Keane M P, Belperio J A, Burdick M, Lynch III J P, Fishbein M F, Strieter R M. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001; 164 2239-2242
106 Nakayama S, Mukae H, Ishii H et al.. Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Respir Med. 2005; 99 1145-1151
107 Renzoni E A, Walsh D A, Salmon M et al.. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med. 2003; 167 438-443
108 Simler N R, Brenchley P E, Horrocks A W, Greaves S M, Hasleton P S, Egan J J. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax. 2004; 59 581-585
109 Cosgrove G P, Brown K K, Schiemann W P et al.. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med. 2004; 170 242-251
110 Strieter R M, Polverini P J, Kunkel S L et al.. The functional role of the “ELR” motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995; 270 27348-27357
111 Keane M P, Arenberg D A, Lynch J P et al.. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997; 159 1437-1443
112 Hyde D M, Henderson T S, Giri S N, Tyler N K, Stovall M Y. Effect of murine gamma interferon on the cellular responses to bleomycin in mice. Exp Lung Res. 1988; 14 687-695
113 Hein R, Behr J, Hundgen M et al.. Treatment of systemic sclerosis with gamma-interferon. Br J Dermatol. 1992; 126 496-501
114 Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. [see comments]. N Engl J Med. 1999; 341 1264-1269
115 Jordana M, Schulman J, McSharry C et al.. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis. 1988; 137 579-584
116 Keane M P, Belperio J A, Moore T A et al.. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol. 1999; 162 5511-5518
117 Strieter R M, Starko K M, Enelow R I, Noth I, Valentine V G. Effects of interferon gamma-1b on biomarker expression in idiopathic pulmonary fibrosis patients. Am J Respir Crit Care Med. 2004; 170 133-140
118 Burdick M D, Murray L A, Keane M P et al.. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med. 2005; 171 261-268

Michael P KeaneM.D.

UCLA, Department of Medicine, Division of Pulmonary and Critical Care Medicine

900 Veteran Ave., 14-154 Warren Hall, Los Angeles, CA 90095-1922

Email: mpkeane@mednet.ucla.edu